摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4-{[(benzyl)(2-bromophenyl)amino]carbonyl}piperidine-1-carboxylate | 293744-31-7

中文名称
——
中文别名
——
英文名称
tert-butyl 4-{[(benzyl)(2-bromophenyl)amino]carbonyl}piperidine-1-carboxylate
英文别名
tert-butyl 4-(benzyl(2-bromophenyl)carbamoyl)piperidine-1-carboxylate;4-[Benzyl-(2-bromo-phenyl)-carbamoyl]-piperidine-1-carboxylic acid tert-butyl ester;tert-butyl 4-[benzyl-(2-bromophenyl)carbamoyl]piperidine-1-carboxylate
tert-butyl 4-{[(benzyl)(2-bromophenyl)amino]carbonyl}piperidine-1-carboxylate化学式
CAS
293744-31-7
化学式
C24H29BrN2O3
mdl
——
分子量
473.41
InChiKey
RITJHUJFOXNBAZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    577.6±50.0 °C(Predicted)
  • 密度:
    1.319±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    30
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    49.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
    申请人:Battista A. Kathleen
    公开号:US20070112016A1
    公开(公告)日:2007-05-17
    The present invention is directed to novel 3-spirocyclic indolyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the ORL-1 receptor.
    本发明涉及新颖的3-螺环吲哚衍生物,包含它们的药物组合物以及它们在治疗由ORL-1受体调节的疾病和症状中的用途。
  • Fused and Spirocycle Compounds and the Use Thereof
    申请人:Chen Zhengming
    公开号:US20090118319A1
    公开(公告)日:2009-05-07
    The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R 1 , R 2 , Q 1 -Q 3 , and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    本发明涉及公式(I)的融合和螺环化合物,或其药学上可接受的盐,前药或溶剂,其中R1、R2、Q1-Q3和Z如说明书所述。本发明还涉及使用公式(I)的化合物治疗、预防或改善对钙通道阻滞有反应的疾病,尤其是N型钙通道。本发明的化合物特别适用于治疗疼痛。
  • Dipiperazinyl ketones and related analogues
    申请人:Xie Linghong
    公开号:US20070049571A1
    公开(公告)日:2007-03-01
    Dipiperazinyl ketones and related analogues are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).
    提供了二吡咯啉酮和相关类似物,以及它们的制备和使用方法。这些化合物通常可用于体内或体外调节组胺H3受体的配体结合,并特别适用于治疗人类、家养伴侣动物和家畜动物的各种疾病。提供了药物组合物和治疗方法,以及使用这些配体检测组胺H3受体的方法(例如,受体定位研究)。
  • ANTAGONISTS OF PGD2 RECEPTORS
    申请人:Stearns Brian Andrew
    公开号:US20100280049A1
    公开(公告)日:2010-11-04
    Described herein are compounds and pharmaceutical compositions containing such compounds that antagonize the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 antagonists, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated conditions or diseases.
    本文描述了一些化合物和含有这些化合物的药物组合物,这些化合物可以拮抗PGD2激活的趋化剂受体同源分子在TH2细胞上的表达(CRTH2)。本文还描述了使用这种CRTH2拮抗剂的方法,单独或与其他化合物联合使用,用于治疗呼吸系统、心血管系统和其他依赖于PGD2或通过PGD2介导的疾病或疾病。
  • 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
    申请人:Janssen Pharmaceutica N.V.
    公开号:US07655670B2
    公开(公告)日:2010-02-02
    The present invention is directed to novel 3-spirocyclic indolyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the ORL-1 receptor.
    本发明涉及新型的3-螺环吲哚衍生物,包含它们的制药组合物以及它们在治疗被ORL-1受体调节的疾病和状况中的应用。
查看更多